soul trial oral semaglutide cardiovascular outcomes 2024 results nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes SOUL (Semaglutide cardiOvascular oUtcomes triaL)

Description

For patients and healthcare providers, the appeal is clear: retatrutide may finally address the full spectrum of metabolic dysfunctionfrom obesity and diabetes to fatty liver diseaseoffering a treatment option that is both broader in scope and more powerful in effect

Full agonism of these GPCRs through both G-protein and -arrestin signaling arms may be suboptimal, promoting undesirable off-target effects and receptor desensitization

Research published in the New England Journal of Medicine found that participants using semaglutide achieved an average weight reduction of nearly 15% of their body weight, substantially outperforming traditional lifestyle interventions alone

While we found weight loss benefits for some patients who switched to phentermine, it is important to remember that individual patient characteristics, lifestyle choices, and personal circumstances are also factors and were not part of this study, Bartelt said